Clinical Trials Browser

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT04384484 2026-01-26

LOTIS 5

Phase 3 Active not recruiting

440 enrolled

Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05023980 2026-01-22

BRUIN CLL-313

Phase 3 Active not recruiting

309 enrolled

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT05737628 2026-01-16

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

Phase 1 Active not recruiting

17 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT06425302 2026-01-08

GOLSEEK-2

Phase 2 Active not recruiting

90 enrolled

Lymphoid

Lymphoma, Lymphoma, Follicular

NCT06970743 2026-01-07

CaDAnCe-303

Phase 3 Recruiting

150 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04182204 2025-12-22

POLARGO

Phase 3 Completed

270 enrolled 36 charts

Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04680052 2025-12-22

InMIND

Phase 3 Active not recruiting

654 enrolled 40 charts 1 FDA

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05952024 2025-12-22

ACRUE

Phase 2 Recruiting

80 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02296918 2025-12-19

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Phase 1 Completed

69 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT07189065 2025-12-16

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Phase 2 Recruiting

150 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

Clinical Trials

MAHOGANY

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

ECHELON-3

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

MK-2140-010

OLYMPIA-1

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

waveLINE-003

SEQUOIA

SUNMO

iMATRIX GLO

OLYMPIA-5

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

EPCORE™ CLL-1

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

EPCORE™ NHL-3

EPCORE™ NHL-2

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

GLOBRYTE

EPCORE™FL-2

EPCORE DLBCL-4

SYMPHONY-1

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

LEDA

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL

GOLSEEK-1

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

POLARIX

OLYMPIA-2

OLYMPIA-4

OLYMPIA-3

Soundtrack-E

Celestimo

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

SIDNEY

BRUIN CLL-322

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

LOTIS 5

BRUIN CLL-313

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

GOLSEEK-2

CaDAnCe-303

POLARGO

InMIND

ACRUE

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma